Uremic pruritus  by Keithi-Reddy, S.R. et al.
Uremic pruritus
SR Keithi-Reddy1, TV Patel2, AW Armstrong3 and AK Singh2
1Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston,
Massachusetts, USA; 2Renal Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA and
3Harvard Dermatology Program, Massachusetts General Hospital, Boston, Massachusetts, USA
CASE PRESENTATION
A 51-year-old African American male with diabetes,
hypertension, and stage 5 chronic kidney disease presents
with intense generalized itching of 1-month duration as
well as nausea and vomiting of 3 days duration. He had no
skin lesions that preceded the onset of itching. The
patient described the itching as predominantly occurring
during the day. He denied any occupational exposure. His
past medical history was notable also for hepatitis C. His
medications included aspirin, neutral protamine hagedorn
insulin, calcitriol, calcium acetate, nifedipine, clonidine,
lisinopril, and furosemide. He had been on these
medications for more than 1 year at varying doses. Social
history was significant for occasional tobacco and alcohol
use as well as crack-cocaine consumption once every 4–6
weeks. There was no significant family history. Pertinent in
the review of systems was the absence of a history of
fever, weight loss, fatigue, or malaise. There was no
history of jaundice. He denied oral or genital ulcers.
Blood pressure at presentation was 158/92 mm Hg and
heart rate 80 beats/min. He was afebrile and had a normal
respiratory rate. The patient had powdery deposits on his
face. He was anicteric. He had bilateral pedal pitting
edema. Examination of skin revealed generalized xerosis
with multiple lichenified patches on the back, chest,
abdomen, upper and lower extremities with more than
90% body surface involved. There were multiple
excoriated 2–4 mm nodules on the lower extremities
bilaterally (Figure 1a) and on the back (Figure 1b). There
were no burrows or vesicles between his finger or toe web
spaces. The oral cavity and genitalia were normal. The rest
of the examination was unremarkable.
Blood work on admission revealed serum electrolytes
within the normal range. Blood urea nitrogen, 93 mg/dl
(normal range 8–18 mg/dl); serum creatinine, 10.8 mg/dl;
blood glucose, 155 mg/dl; liver function tests including
transaminases and bilirubin were within normal limits;
serum albumin, 3.6 g/dl (normal range 3–5 g/dl); serum
calcium, 7.7 mg/dl; serum phosphate, 4.4 mg/dl; intact-
parathyroid hormone (iPTH), 266 pg/ml. White blood cell
count was 9.58 106/l (normal range 4.5–11 106/l),
white blood cell count differential: segmented neutrophils
54% (normal range 54–62%), lymphocytes 15.9% (normal
range 25–33%), and monocytes 5.8% (normal range 3–7%),
eosinophils 24% and less than 5% band forms. Peripheral
smear examination revealed anisomicrocytosis with burr
cells and spherocytes. Antinuclear antibody was negative.
Thyrotropic hormone was 2.38 mU/ml.
SKIN BIOPSY FINDINGS
A punch-skin biopsy from the left thigh was performed. The
biopsy revealed perivascular inflammation with eosinophils,
dermal hemorrhage, and psoriasiform hyperplasia with
spongiosis, rare apoptotic keratinocytes and parakeratosis.
A Periodic acid-Schiff digested stain stain was negative for
fungal elements and a Congo red stain was negative for
amyloid (Figure 2a and b).
FINAL DIAGNOSIS
Uremic pruritus.
FOLLOW UP
Given the typical histological findings from the skin biopsy in
the setting of advanced renal failure, a diagnosis of uremic
pruritus was made. Other possibilities that are associated
with itching in end-stage renal disease patients were also
considered in the differential diagnosis (Table 1). Drug-
induced hypersensitivity was a possibility; however, the
patient had not been treated with any new medication. The
eosinophilia was most probably from the uremic pruritus
state, as mast cells and histamine release is implicated in the
pathogenesis (as discussed below). The PTH level was within
the range recommended by Kidney Disease Outcomes
Quality Initiative guidelines. Furthermore, there was no
significant interval change that could have plausibly ex-
plained the abrupt onset of itching. The absence of jaundice
and the normal liver function tests ruled out the possibility of
cholestatic hepatitis. The patient was initiated on dialysis. He
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was also treated with topical corticosteroids (1% hydro-
cortisone) and an anti-itch ointment containing 0.5% each
of camphor and menthol in an emollient base. After 3 weeks
of dialysis, his pruritus had substantially improved. The
skin lesions improved with a short course of the topical
agents and adequate dialysis treatment (urea reduction
ratio 76%).
DISCUSSION
Uremic pruritus
Itching in patients with advanced kidney failure or among
patients on dialysis can be quite disabling – affecting sleep,
interfering with work, and potentially compromising quality
of life.1 The itching may be either generalized or localized.
The prevalence of uremic itching reported in the literature
ranges between 50 and 90%.2 Risk factors include male
gender, high levels of blood urea nitrogen, elevated calcium,
phosphorus and b2-microglobulin levels.1 Despite advances
in the care of end-stage renal disease (ESRD) patients, the
management of pruritus remains one of the most challenging
clinical problems for the treating nephrologist. Although the
association of uremia with pruritus has been recognized for
many years, the precise pathophysiologic mechanisms remain
obscure.
a
b
Figure 1 | Examination of skin. (a) Intense skin rash on the lower
extremity. (b) Intense skin rash on the back.
a
b
Figure 2 | Skin biospy findings. (a) Superficial perivascular
lymphocytic infiltrate with eosinophils, dermal hemorrhage, and
psoriasiform hyperplasia. Periodic acid-Schiff digested stain negative
for fungal elements (original magnification  10). (b) Superficial
perivascular, predominantly lymphocytic infiltrate with eosinophils
(original magnification  40).
Table 1 | Causes of itching in end-stage renal disease patients
(1) Uremia related
(a) Uremic itching
(b) Xerosis
(c) Anemia of chronic kidney disease
(d) Secondary hyperparathyroidism
(2) Uremia unrelated
(a) Drug-induced hypersensitivity
(b) Senility
(c) Hepatitis
(d) Diabetes mellitus
(e) Hypothyroidism
(f) Iron-deficiency anemia
(g) Lymphoproliferative/solid tumors
(h) Hypercalcemic states
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Pathogenesis of uremic pruritus
Nearly 40 years ago, Massry et al.3 suggested a prominent role
for secondary hyperparathyroidism and associated derange-
ments of calcium and phosphorus metabolism in the
pathogenesis of uremic pruritus. There are conflicting reports
with respect to correlation of pruritus with elevated iPTH.4
Although PTH itself is not pruritogenic when injected into
the skin, elevated Ca P product is strongly correlated with
pruritus. Apart from the above-described factors, possible
roles for abnormal skin innervation, somatic neuropathy,
elevated histamine levels, and opioid receptors have also been
suggested (Figure 3).5
Neurophysiological factors are considered to play an
important role in ESRD-associated pruritus. Pruritus is
thought to originate in the terminal branching of afferent
nonmyelinated C fibers distinct from those involved with
pain that are located in the lower epidermis or dermal–
epidermal junction. Mast cells in the dermis lie adjacent to
afferent C neuron terminals and interactions between these
structures play an important role in the mediation of
pruritus.6 Mast cells release several substances such as
histamine, proteases, interleukin-2, and tumor necrosis
factor. Histamine is a well-known pruritogen that directly
stimulates the neurons terminals by H1 receptor. One study
suggested abnormal sprouting of intraepidermal neuron-
specific enolase – immunoreactive nerve fibers in uremic
patients. This suggested abnormal pattern of cutaneous
innervations as a presumptive cause for pruritus in ESRD
patients.5 It has also been observed that substance P
stimulates m-opioid receptors in peripheral nerves and brain,
and altered balance between m-opioid and k-opioid stimula-
tion leads to itching. The effects of m-opioid stimulation and
substance P are countered by the stimulation of k-opioid
receptors by novel k-opioid agonist, nalfurafine. These
studies in animal models and subsequently in a subset of
ESRD patient population have established a convincing role
for m-opioid receptors in ESRD-associated pruritus.7
Several other factors are implicated in the pathogenesis of
itching in uremic patients. Xerosis (dry skin) is very prevalent
in ESRD patients.8 Although association of xerosis with
pruritus has been inconsistent, it may explain the higher
prevalence of pruritus in elderly patients with ESRD.
Additional factors that have been suggested as potential
etiologies of pruritus in ESRD patients include high serum
levels of magnesium, aluminum, and substance P; hypervi-
taminosis A and peripheral neuropathy. Anemia has also
been suggested as an important predisposing factor, although
definitive proof has been elusive.9 More recently, with a
substantial body of evidence accumulated in favor of the
concept that the uremia is an inflammatory state, uremic
pruritus is considered as a skin counterpart of chronic
ongoing inflammation in these patients. Serum albumin was
found to be lower in patients with severe pruritus in
comparison to those without this symptom. Some studies
have corroborated these findings and showed severity of
pruritus correlates with poor survival and dialysis inade-
quacy.10 The uremic inflammatory state also explains higher
number of mast cells in dermis. However, a study which
analyzed the number of dermal mast cells and serum levels of
histamine did not show any correlation with the degree of
pruritus.11 Finally, a high prevalence of HLA-B35 reported in
pruritic ESRD patients suggested genetic predisposition.
Regardless of the mechanism, the final common pathway
appears to be the release of histamine from mast cells. This is
supported by the observation that ultraviolet-B phototherapy
reduced mast cell number and improved itching significantly,
though there is no correlation between mast cell number and
severity of pruritus in ESRD patients.11
Diagnosis of uremic pruritus
Uremic pruritus is often considered a misnomer for the
following reasons: pruritus in ESRD patients is not universal;
it does not correlate with severity of uremia; even high-flux
dialysis does not alleviate the problem; and pruritus is not
seen in acute renal failure patients. A skin biopsy in patients
with uremic pruritus is usually inconclusive. Repetitive
scratching leads to excoriations, which in turn leads
to superimposed dermatologic conditions, such as lichen
simplex, prurigo modularis and keratotic papules (a
perforating folliculitis), and follicular hyperkeratosis.12 For
epidemiological purposes, specific criteria are used to
diagnose uremic pruritus (Table 2).
Management
Renal transplantation remains the only current definitive
treatment for severe refractory uremic pruritus in ESRD
patients. However, this is frequently not feasible or may not
be immediately possible. Therefore, a reasonable approach is
to optimize the dialysis dose,1 treat with erythropoietin9 and
iron supplementation, and treat secondary hyperparathy-
roidism with a view to maintaining the calcium and
phosphate product at o55. Several treatment modalities
have been tried in the treatment of uremic pruritus. However,
the evidence for most of the therapies is based on
uncontrolled trials or case series (Table 3).
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Figure 3 | Working model for pathogenesis of uremic pruritus.
(1) Several substances have been proposed to produce pruritogenic
environment. (2) Histamine released from mast cells, in response to
pruritogenic substances, stimulates C-terminal nerve endings.
(3) A cascade of signals from nerve endings activate specific areas
in the central nervous system resulting in perception of itch. (4) By a
direct axon reflex mechanism, sensory nerve endings release
neuropeptides. (5) Locally released neuropeptides aggravate the itch
response by stimulating accumulation of inflammatory cells and
release of pruritic mediators.
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The most prevalent finding in uremic patients is xerosis.
Evidence supports use of emollients, such as aqueous gel
containing 80% water in the treatment of pruritus. In an
uncontrolled study, 16 out of 21 patients studied had
significant relief from symptoms, out of whom nine reported
complete abolition of symptoms of pruritus.13 Patients can
be advised to use mild soaps and apply these moisturizing
emollients atleast twice daily.
The role of UVB has been shown to be therapeutic in renal
pruritus in double-blind trials.14 It is considered as a safe and
convenient therapy for uremic pruritus. The mechanism of
the antipruritic effect of UVB is not completely understood.
Among the proposed mechanisms are inactivation of a
circulating pruritogenic substance, formation of a photo-
product, which relieves pruritus, alteration of divalent ion
content in the skin, and promotion of cutaneous-nerve
degeneration.
Immune dysregulation and altered pattern of lymphokine
production are considered to be major contributory factors
for pruritus. Essential fatty acids such as g-linolenic acid
(GLA) reduce lymphocyte proliferation and lymphokine
production and decrease severity of itching. A recently
published prospective, randomized, double-blind, placebo-
controlled, crossover study addressed this issue.15 In this
study, patients were randomly assigned to treatment with
either 2.2% GLA cream or placebo-based cream applied three
times a day for 2 weeks and then patients were crossed over
to the opposite group. Severity of pruritus was evaluated by
using a traditional visual analogue scale and a modified
questionnaire method in 16 patients. There was a greater
antipruritic effect of GLA and persistence of a residual effect
into the second treatment period after GLA treatment. In
another study, nine and seven patients were randomly
assigned and treated withGLA-rich evening primrose oil or
linoleic acid, respectively, for 6 weeks.16 Uremic symptoms
such as dryness, pruritus and erythema, and plasma
concentrations of essential fatty acids were analyzed. The
patients given oral GLA-rich evening primrose oil exhibited a
significant improvement in skin scores and increase in
precursors of anti-inflammatory prostaglandins with no
concomitant alterations in proinflammatory prostaglandin
precursors suggesting that it is a better supplemental source
than linoleic acid alone in terms of shifting eicosanoid
metabolism towards anti-inflammatory state.
Capsaicin 0.025% cream is another topical agent tried in
the management of uremic pruritus.17 Local application of
capsaicin depletes the peripheral neurons of substance P and
blocks the conduction of pain or pruritus. In this study, 14
out of 17 patients reported marked relief and five out of these
14 patients had complete remission of pruritus during
capsaicin treatment. Capsaicin was significantly more effec-
tive than placebo with prolonged antipruritic effect up to 8
weeks post-treatment.
As imbalance in m- and k-opioid stimulation has been
implicated in the pathogenesis, manipulation of opioid
system in the body has been attempted in the management
of pruritus. Naltrexone, an opioid antagonist, is effective in a
subset of patients with uremic pruritus.18 However, in a
placebo-controlled, double-blind crossover study of uremic
patients with persistent, treatment-resistant pruritus, there
was no significant difference between naltrexone and
placebo.19 Given this conflicting results and high incidence
of gastro–intestinal adverse events, naltrexone is not con-
sidered a preferred drug in uremic pruritus. Nalfurafine, a
new k-opioid receptor agonist, was tried in the treatment of
uremic pruritus. In a meta-analysis of two multicenter,
randomized, double-blind, placebo-controlled studies on
adult hemodialysis patients who had severe intractable
pruritus, patients were randomized to receive nalfurafine
5 mg or placebo intravenously three times a week, after each
dialysis session for 2–4 weeks. Primary outcome measures
decreased in worst itching visual analogue scale score.
Secondary outcome measures were daytime itching intensity
and sleep disturbances.7 Significantly, more nalfurafine-
treated patients responded within 2 weeks of run-in than
placebo group (36 versus 14%). Drug-related side effects were
comparable between the groups.
Table 2 | Criteria for the diagnosis of uremic pruritus20
1 Pruritus appears shortly before the onset of dialysis, or at any time,
without evidence of any other active disease that could explain the
pruritus.
2 more than or equal to three episodes of itch during a period of o2
weeks, with the symptom appearing a few times a day, lasting at least
few minutes, and troubling the patient.
3 Appearance of an itch in a regular pattern during a period of 6
months, but less frequently than listed above.
Table 3 | Therapeutic options in uremic patients
Dialysis related
(a) Renal transplantation
(b) Efficient dialysis
(c) Erythropoietin
Topical treatment
(a) Skin emollients
(b) Capsaicin
(c) Topical steroids
Physical treatment
(a) Phototherapy
(b) Acupuncture
(c) Sauna
Systemic treatment
(a) Low-protein diet
(b) Primrose oil
(c) Lidocaine and mexilitine
(d) Opioid antagonists
(e) Activated charcoal
(f) Cholestyramine
(g) Serotonin antagonists
(h) Parathyroidectomy
(i) Thalidomide
(j) Nicergoline
(k) Nalfurafine
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In summary, uremia remains the commonest cause of
pruritus in ESRD patients, although it represents a diagnosis
of exclusion. Uremic pruritus may have diverse skin
manifestations and these frequently mimic a drug-induced
hypersensitivity reaction. The early diagnosis and prompt
treatment of uremic pruritus focuses on some general
strategies that include the optimization of dialysis dose,
erythropoietin, and management of secondary hyperpara-
thyroidism. More specific treatments that appear promising
but have not been proven to be definitively efficacious
include UVB light, and the novel k-opioid-agonist nalfur-
afine leads to significant improvement.
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